Approval Pathway News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Has had with lawmakers this week. This is what he said in the last hour. We cant do too much here. We can do too little. We can do too little and sputter. The end result is, its not just a Macro Economic impact on the economy and our ability to compete internationally. Its peoples lives. Real live people are hurting. We can fix it. We got the first jobs report out under President Biden. Its a better report than december. Overall though, we have a long way to go. 49,000 jobs were added last month. The Unemployment Rate fell to 6. 3 in january. We will take a closer look in moments. I want to st...

in a century. history going on here. welcome to another hour of "america's newsroom." i'm dana perino. >> bill: missed you. happy new year. >> dana: i missed you. are you glad to be back? >> bill: with you absolutely. i'm bill hemmer. happy new year at home. the house is getting ready to end the 117th congress. the senate will do the same later this morning. the new house could convene in about two hours, 12 noon with a vote for speaker expected to begin around 1:00 eastern time. >> dana: five republicans have said they oppose mccarthy for speaker but can only afford to lose four vot...

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger ...

06.03.2023 - Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with a Prescription Drug User Fee Act ...

Deviated from fda guidance and procedures in significant respects. they are accusing the fda of working with biogen, the manufacturer of the drug, to approve the drug, promote it and rush it to market. even putting together joint presentations between the fda and biogen advocating for the drug's effectiveness. the fda not acknowledging any wrongdoing but doubling down on their practices. quote, fda remains committed to the integrity of our drug approval process and will continue to use the accelerated approval pathway that they used here. b biogen says they stand by the integrity of the action...